ASCO 2024 - Dr. Jane Lowe Meisel Presents I-SPY2.2 Trial Results on Datopotamab Deruxtecan for High-Risk HER2-Negative Breast Cancer

ASCO 2024 - Dr. Matthew P. Goetz on the ELAINE 3 Study: Lasofoxifene and Abemaciclib in ER+/HER2- Advanced Breast Cancer

ASCO 2024 - Dr. Jean-Pierre Ayoub Reviews DESTINY-Breast06: Trastuzumab Deruxtecan's Impact on Progression-Free Survival

ASCO 2024 - Dr. Nagi S. El Saghir on New Advances in Sequencing CDK4/6 Inhibitors with Endocrine Therapy in Advanced Breast Cancer

ASCO 2024 - Dr. Mark Basik Highlights TRICIA Study Results in Triple Negative Breast Cancer